Enliven Therapeutics, Inc.

NasdaqGS:ELVN Stock Report

Market Cap: US$3.5b

Enliven Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Enliven Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-6.5%

Buyback Yield

Total Shareholder Yield-6.5%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Seeking Alpha • Jun 22

Enliven Therapeutics: Continuing The Pop Off; What Could Go Wrong?

Summary Enliven Therapeutics has demonstrated strong early data for ELVN-001 in heavily pretreated CML, with a phase 3 trial imminent. ELVN is extremely well-capitalized, boasting nearly $800 million in liquidity and a multi-year operational runway, even before a $400 million public offering. Despite promising clinical progress, ELVN's $3 billion valuation far exceeds what current data and market analogs justify, given no near-term commercial product. I maintain a 'Sell' rating, expecting a more attractive entry point as the market's enthusiasm outpaces realistic commercial prospects for ELVN-001. Read the full article on Seeking Alpha
Analysis Article • Apr 27

We're Not Worried About Enliven Therapeutics' (NASDAQ:ELVN) Cash Burn

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Aug 15

Companies Like Enliven Therapeutics (NASDAQ:ELVN) Are In A Position To Invest In Growth

NasdaqGS:ELVN 1 Year Share Price vs Fair Value Explore Enliven Therapeutics's Fair Values from the Community and select...
Seeking Alpha • Apr 22

Enliven Therapeutics: Awaiting Additional Trial Data

Summary Today, I take my first look at Enliven Therapeutics, Inc., a clinical-stage concern that has two candidates in its pipeline targeting oncology indications. Enliven ended FY2024 with over $310 million in cash and marketable securities, with no long-term debt and funding secured until mid-2027. The analyst firm community is optimistic about the prospects for Enliven Therapeutics, but insider selling over the past year is somewhat bothersome. An analysis of Enliven Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Analysis Article • Apr 01

We Think Enliven Therapeutics (NASDAQ:ELVN) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Jan 07

Enliven's Early Data Stands Out From Peers

Summary Enliven Therapeutics' ELVN-001 shows promising interim data, achieving a 44% major molecular response rate in heavily pre-treated CML patients within 12 weeks. ELVN-001 targets the BCR-ABL gene fusion, addressing resistance issues seen with other TKIs, including the T315I mutation. Financially, Enliven has a market cap of $1.9bn and a cash runway of 7–8 quarters, supporting continued R&D efforts. Despite early-stage data risks, ELVN-001's strong profile and unmet medical need make it a speculative buy at slightly lower prices. Read the full article on Seeking Alpha
Analysis Article • Dec 14

Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Aug 29

We Think Enliven Therapeutics (NASDAQ:ELVN) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ELVN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ELVN's dividend payments have been increasing.

Dividend Yield vs Market

Enliven Therapeutics Dividend Yield vs Market
How does ELVN dividend yield compare to the market?
SegmentDividend Yield
Company (ELVN)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.1%
Industry Average (Pharmaceuticals)1.9%
Analyst forecast (ELVN) (up to 3 years)n/a

Notable Dividend: Unable to evaluate ELVN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ELVN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ELVN's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ELVN has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/29 09:00
End of Day Share Price 2026/06/26 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Enliven Therapeutics, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Salveen RichterGoldman Sachs
Michael SchmidtGuggenheim Securities, LLC